Drug Profile

Pitavastatin - Palvella Therapeutics

Alternative Names: QTORIN™ pitavastatin - Palvella Therapeutics

Latest Information Update: 28 Nov 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Palvella Therapeutics
Class Alcohols; Alkenes; Antihyperlipidaemics; Carboxylic acids; Cyclopropanes; Fluorobenzenes; Quinolines; Skin disorder therapies; Small molecules
Mechanism of Action HMG-CoA reductase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Preclinical Skin disorders

Most Recent Events

16 Nov 2025 Chemical structure information added.
05 Nov 2025 Palvella Therapeutics has patents pending for QTORIN™ pitavastatin formulation and method of use
05 Nov 2025 Preclinical trials in Skin disorders in USA (Topical) prior to November 2025

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com